INTRODUCTION
============

Familial hypercholesterolemia (FH) is a common autosomal dominant genetic disorder and is an important health issue \[[@B1][@B2]\]. Patients with FH are exposed to a lifetime burden of high low density lipoprotein cholesterol (LDL-C) and have significantly increased cardiovascular risk. Therefore, early and appropriate diagnosis in affected persons and prevention of vascular complications are critical. In this review, recent studies on the prevalence, diagnosis, vascular risk, and treatment of patient with FH are discussed. Particularly, the focus is on studies of heterozygous FH.

PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA
===========================================

The frequency of heterozygous FH has long been reported to be 1/500 (0.2%), while that of homozygous FH has been reported to be 1/1,000,000 in many studies conducted in various countries around the world \[[@B3]\]. However, although heterozygous FH is influenced by diagnostic criteria including mutation positivity, the prevalence has been reported to be 1/217 in a very recent Danish study \[[@B4]\] and 1/250 in an American study using Dutch criteria \[[@B5]\].

CLINICAL AND GENETIC DIAGNOSIS
==============================

Clinical criteria most commonly used for diagnosis of FH include the Simon Broome Register Group criteria \[[@B6]\], Dutch Lipid Clinic Network criteria \[[@B6]\], and Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria \[[@B7]\]. A Japanese group has also developed their own criteria for FH \[[@B8]\]. Major items for these clinical diagnostic criteria are (1) severe hypercholesterolemia; (2) physical findings such as xanthoma in the index case; and (3) family history of premature coronary artery disease (CAD) or severe hypercholesterolemia. While the above-mentioned criteria designed in different countries show similarity, they also show difference with respect to specific values ([Table 1](#T1){ref-type="table"}). For cost-effective and efficient diagnosis, many guidelines and expert groups recommend cascade genetic screening for family members. However, in real practice, diagnosis using only clinical findings from history taking, physical examination, and lipid profile is very common, especially when genetic screening is not available \[[@B1]\].

Most monogenic causes of FH are mutations of low density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes. All of these genes are involved in the pathway that clears circulating low-density lipoprotein \[[@B9]\]. Among monogenic FHs, about 90% are caused by mutations of *LDLR*, for which ≥1,200 different mutations have been identified \[[@B1]\]. However, even family members who have the same mutation often have quite different LDL-C levels, responsiveness to lipid lowering therapy, and survival. Therefore, decision of whether to treat or the intensity of treatment depends mostly on the phenotype rather than genotype. In other words, the clinical importance of genetic diagnosis is limited, and clinical diagnosis is emphasized in real clinical practice \[[@B10]\]. Pathogenic mutations are not identified in about 60% of clinically diagnosed FH patients, although the proportion differs according to the ethnicity or diagnostic criteria. Most FH patients without a monogenic cause are suspected to have polygenic FH that is caused by a multiple lipid-related common variants \[[@B2]\].

Although LDL-C \>500 mg/dL or a xanthoma in a child is suspicious for homozygous FH, some patients with homozygous FH have lower LDL-C levels \[[@B11]\].

CARDIOVASCULAR RISK IN FAMILIAL HYPERCHOLESTEROLEMIA
====================================================

The most critical complication in FH is life-time cardiovascular disease due to longstanding LDL-C burden ([Fig. 1](#F1){ref-type="fig"}). It has been reported that 25% of affected women and 50% of affected men experience cardiovascular complications \[[@B12]\]. The risk of CAD is known to be 3.5- to 16-fold higher in heterozygous FH patients compared to non-FH individuals \[[@B13]\]. The results of studies on the risk of cerebrovascular disease have been inconsistent and the risk is not yet clear \[[@B14]\]. The guidelines recommend that risk assessment in patients with FH should not be made according to European Systematic Coronary Risk Estimation or American Framingham Risk Score, because these scoring systems underestimate cardiovascular risk in FH \[[@B1]\]. Even with the same LDL-C levels, carriers of mutations for FH show higher risk for CAD \[[@B15]\]. In addition, cardiovascular risk in FH is also influenced by other traditional risk factors, and these often also need to be considered when determining treatment \[[@B14][@B16]\].

THE GOALS AND RESULTS OF LIPID-LOWERING TREATMENT AND NOVEL THERAPEUTICS
========================================================================

The main purpose of preventive measures in FH is the reduction of cardiovascular risk. Thus, it is essential to implement pharmaco- and non-pharmacotherapy targeting hypercholesterolemia and other combined risk factors as well. As mentioned above, because vascular risk is very high and associated with cholesterol burden, lowering LDL-C is the mainstay of cardiovascular prevention in FH. Most recent guidelines indicate that it is desirable to reduce LDL-C to 50% of baseline levels or \<100 mg/dL in adults with FH. Statins are the first-line agent and ezetimibe or cholesterol-binding resins are recommended when needed \[[@B17]\]. Data from the United Kingdom have demonstrated that the mortality of patients with FH decreased by 25% to 48% after introduction of statins \[[@B18]\]. Earlier treatment is important for efficient prevention of vascular complications. However, because the evidence is limited, there is no sufficient consensus on when to start treatment in children with FH \[[@B19][@B20][@B21]\].

Lipoprotein apheresis can be considered in patients with persistently high LDL-C after treatment, extremely high cardiovascular risk, statin intolerance, or especially in patients who have homozygous FH \[[@B1]\]. Meanwhile, the achievement rate of LDL-C goal (\<100 mg/dL) is reported to be 11% \[[@B14]\] and a large part of patients do not reach the target. Therefore, PCSK9 inhibitors, recently approved lipid-lowering agents, are spotlighted and expected to meet the unmet medical need ([Table 2](#T2){ref-type="table"}) \[[@B22][@B23]\]. Although two PCSK9 inhibitors, evolocumab and alirocumab, have shown consistent and strong lipid-lowering efficacy, limitation is their high cost \[[@B24]\]. Lomitapide inhibits microsomal triglyceride transfer protein and reduces very low density lipoprotein (VLDL) assembly, whereas mipomersen blocks the translation of apoB and decreases VLDL synthesis. These two agents were approved for the treatment of homozygous FH. However, drug-related adverse events are relatively frequent and risk/benefit ratio needs to be taken into account for these drugs ([Table 2](#T2){ref-type="table"}) \[[@B22][@B23]\].

FAMILIAL HYPERCHOLESTEROLEMIA IN ASIA AND KOREA
===============================================

Although Asian data on FH are not sufficient, its reported prevalence is similar to that of Western countries. The average cholesterol level in Asian patients with FH is likely lower \[[@B25]\]. A recent Korean study suggested that the best cutoff values for predicting mutation-positive FH are total cholesterol 310 mg/dL and LDL-C 225 mg/dL \[[@B26]\]. In Asian patients, 80% to 100% of causing mutations were identified in *LDLR*, whereas the others were found in *APOB* or *PCSK9* \[[@B25][@B26]\]. Three of 10 Korean FH patients revealed history of CAD. However, the achievement rate of LDL-C by conventional lipid-lowering therapy was not satisfactory \[[@B27]\].

CONCLUSIONS
===========

FH is a relatively frequent genetic disorder. Diagnosis of FH by clinical rather than genetic criteria is more common in real world practice. Reduction of premature complications is most critical in patients with FH. Although, the majority of patients cannot reach a LDL-C goal by conventional pharmacotherapy, novel therapeutics such as PCSK9 inhibitors are expected to improve treatment results.
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![Low density lipoprotein cholesterol (LDL-C) burden in individuals with or without familial hypercholesterolemia (FH) as function of the onset of statin therapy. Adapted from Nordestgaard et al. \[[@B7]\], with permission from Oxford University Press. CHD, coronary heart disease; HDL-C, high density lipoprotein cholesterol.](enm-32-36-g001){#F1}

###### Characteristics of Four Clinical Diagnostic Criteria
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                         Simon Broome                                                                                                     Dutch                                                                                                                                                      MEDPED                                                 Japanese
  ---------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------
  Process of diagnosis   Mutation or cholesterol plus xanthoma or family history                                                          Sum of score for each item                                                                                                                                 Cholesterol level alone                                Any two of cholesterol, xanthoma, or family history
  Items                  Total cholesterol \>290 or LDL-C \>190 mg/dL; xanthoma; mutation; family history of MI or hypercholesterolemia   Family history of CAD or hypercholesterolemia; history of CAD, cerebral or peripheral vascular disease; xanthoma or corneal arcus; LDL-C ≥150--330 mg/dL   Total cholesterol ≥290--360 or LDL-C ≥220--260 mg/dL   LDL-C ≥180 mg/dL; xanthoma; family history of hypercholesterolemia or CAD

MEDPED, Make Early Diagnosis to Prevent Early Deaths; LDL-C, low density lipoprotein cholesterol; MI, myocardial infarction; CAD, coronary artery disease.

###### New Therapeutics Approved for Familial Hypercholesterolemia
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                     Lomitapide                                                                         Mipomersen                                                                                                                      PCSK9 inhibitors (evolocumab, alirocumab)
  ------------------ ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Action mechanism   Inhibition of microsomal TG transfer protein; reduction of VLDL synthesis          Antisense oligonucleotide that binds to mRNA and blocks apoB translation                                                        Binds to plasma PCSK9, reduces endosomal degradation of LDLR
  Efficacy           Lowers LDL-C & apoB by 40%--50% on top of ongoing therapy                          Lowers LDL-C & apoB by 20%--30% and lp(a) by 20%--25% on top of ongoing therapy                                                 Lowers LDL-C by 50%--60%, apoB by 40%--50%, and lp(a) by 20%--30%; 50% reduction of cardiovascular events in preliminary data
  Safety             GI disturbance (\>90%), liver enzyme elevation (14%--34%), and hepatic steatosis   Injection-site reaction (\>75%), influenza-like symptoms (30%--65%), liver enzyme elevation (12%--15%), and hepatic steatosis   Largely well tolerated; slight injection-site reactions, neurocognitive and muscle-related symptoms
  Remarks            Approved in USA for hoFH                                                           Approved in USA, Canada, and Europe for hoFH                                                                                    Approved in USA and Europe for FH

PCSK9, proprotein convertase subtilisin/kexin type 9; TG, triglyceride; VLDL, very low density lipoprotein; apoB, apolipoprotein B; LDLR, low density lipoprotein receptor; LDL-C, low density lipoprotein cholesterol; lp(a), lipoprotein(a); GI, gastrointestinal; hoFH, homozygous familial hypercholesterolemia; FH, familial hypercholesterolemia.
